Artelo Biosciences Reports 2nd Quarter Fiscal 2021 Money Final results and Delivers Business Update
Not long ago Commenced Affected person Enrollment in Period 1/2 CAReS Study of Art27.13 in the British islesNoted Favourable Pre-Medical...
Not long ago Commenced Affected person Enrollment in Period 1/2 CAReS Study of Art27.13 in the British islesNoted Favourable Pre-Medical...
SAN FRANCISCO--(Organization WIRE)--Apr 12, 2021--Zendesk, Inc. (NYSE: ZEN) now declared that it will release fiscal outcomes for the very first...
SEATTLE, April 07, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development...
MEXICO CITY, April 7, 2021 /PRNewswire/ -- Grupo Aeromexico S.A.B. de C.V. ("Aeromexico") (BMV: AEROMEX) today reported March 2021 operational...
Phase 2b dry AMD patient recruitment completed with topline data expected Q2 2022NDA submission for elamipretide for cardiomyopathy in Barth...
Updates guidance for fiscal year 2022, adds additional strategic partnerships, expands salesforceE2open (NYSE: ETWO), a leading network-based provider of 100%...
Charlie's PMTA is in Substantive Review with the FDAQ4 Showed 15% Increase in Quarterly RevenueCOSTA MESA, CA / ACCESSWIRE /...
Implements new corporate strategy to focus on precision therapeutics for the treatment of cancer Strengthens pipeline by acquiring a proprietary...
RICHARDSON, Texas--(BUSINESS WIRE)--Apr 2, 2021--Fuse Medical, Inc. (OTCPINK: FZMD) (“Fuse” or the “Company”) an emerging manufacturer and distributor of innovative...
PEMBROKE, Bermuda--(Business WIRE)--Apr 1, 2021--RenaissanceRe Holdings Ltd. (NYSE: RNR) (the “Company” or “RenaissanceRe”) will carry out an financial commitment group...
RESTON, Va.--(Business WIRE)--Apr 1, 2021--VeriSign, Inc. (NASDAQ: VRSN), a worldwide provider of domain title registry services and web infrastructure, currently...
VAB shares 23 authentic-world model circumstance reportsNEW YORK, April 1, 2021 /PRNewswire/ -- VAB's Proven Tactics & Practices In Viewers-Based...
Plans to have three AAV gene therapy programs in the clinic by year-end 2021Data from FLT180a Phase 1/2 trial for...
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - April 1, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF)...
Clinical evaluation of AM-301 nasal spray in allergen protection progressingLaunch of AM-301 expected in selected markets towards the end of...
Enrollment complete for Saturn-1, first TP-03 pivotal trial for the treatment of Demodex blepharitis; initiation of Saturn-2 expected in Q2...
2020 Full Year Net Revenue of $32.4 Million Up 34% vs Prior Year; Fourth Quarter Net Revenue of $9.6M Million...
~ Fennec is Working Closely with its Third-Party Drug Product Manufacturer to Finalize the New Drug Application (NDA) Resubmission for...